INTRODUCTION
============

Apolipoprotein E (ApoE) is a 34-kDa glycoprotein with 299 amino acids that is mainly synthesized in the liver. The apoE gene with 3.6 kb is located on chromosome 19q13.32 \[[@b1-pi-2019-0090]\]. *APOE* has three major isoforms, *APOE2*, *E3*, and *E4*, which are encoded by three alleles (*E2*, *E3*, and *E4*), resulting in six different genotypes (*E2*/*E2*, *E3*/*E3*, *E2*/*E3*, *E3*/*E4*, *E2*/*E4*, and *E4*/ *E4*) \[[@b2-pi-2019-0090],[@b3-pi-2019-0090]\]. The *E3* allele differs from the *E2* allele by change cysteine to arginine at codon 158, while the *E4* differs from *E3* by a substitution of arginine for cysteine at residue 112. ApoE protein plays an important role in lipoprotein metabolism. *E2* allele was associated with decreased plasma cholesterol level but *E4* with elevations in LDL-C. Moreover, some studies have reported that the *E4* allele is associated with the risk of coronary heart disease \[[@b4-pi-2019-0090]\].

Brain atrophy was mainly caused by cell apoptosis and considered as an irresistible physiological process, characterized by widening of the sulci, decreased specific grey or white matter volumes and increased ventricular volumes, which was a common finding on MRI in the elderly \[[@b5-pi-2019-0090],[@b6-pi-2019-0090]\]. White matter disease (WMD) was a neuroimaging term, also known as leukoaraiosis (LA). The concept of LA was first proposed by Hachinski in 1987 \[[@b7-pi-2019-0090]\]. WML appeared as a speckled or patchy change in the subcorolla or periventricular white matter, showing a low-density lesion on CT, and also T1WI image with low signal or an equal signal, and the T2WI and T2 FLAIR images with high signals on the MRI. In addition to brain atrophy, WML was considered as the result of cerebral small-vessel disease and also often found on MRI in the elderly \[[@b8-pi-2019-0090],[@b9-pi-2019-0090]\]. Brain atrophy and WML had many of the same features as followed. First, evidence has accumulated that vascular factors including hypertension, hyperlipidemia, diabetes mellitus, obesity, alcohol, and smoking play an important role in the etiology of brain atrophy and WML \[[@b10-pi-2019-0090]\]. Second, they were associated with future cognitive decline and dementia \[[@b11-pi-2019-0090],[@b12-pi-2019-0090]\]. Then, they were common accompaniment of ageing and accelerate in older age.

Several studies had demonstrated the association of *APOE* polymorphisms with cardiovascular and nervous system diseases, Alzheimer's disease, diabetic nephropathy, atherosclerosis, diabetes \[[@b13-pi-2019-0090],[@b14-pi-2019-0090]\]. Few studies had investigated apoE polymorphism in the Chinese population with White matter lesions and/or brain atrophy. More recently, concomitant brain atrophy and WML have frequently been observed in elderly people on magnetic resonance imaging (MRI). However, it is unknown which factors may explain the co-occurrence of WML and brain atrophy. Therefore, the objective of this study was to assess the genetic associations of *APOE* allele/genotype frequencies in patients with White matter lesions and/or brain atrophy.

METHODS
=======

Participants
------------

Patients and controls were recruited from Renmin Hospital of WuHan University, Hubei Province in China from January 2018 to December 2018. This study included 393 participants, which consisted of 58 patients with White matter lesions, 128 patients with White matter lesions, 112 patients with White matter lesions and 95 healthy elderly volunteers who underwent a regular health examination as healthy controls. WMLs was identified on MRI scan and its severity was graded using the Fazekas method to include a score for the deep white matter and periventricular regions when patients were rechecked MRI scan \[[@b15-pi-2019-0090]\]. The brain atrophy disease was scored on the frontal, temporal, and parietal atrophy by the cortical atrophy scale and the subject's head MRI T1 image \[[@b16-pi-2019-0090]\]. The above assessment was performed by two neurologists who were blinded to the basic information of the patients. Written informed consent was obtained from all participants before the collection of biological samples, and the protocol was approved by the Medical Ethics Review Committee of Renmin Hospital of WuHan University (WDRY2019-K105).

Biochemical measurement
-----------------------

Approximately 5 mL of blood was taken from each study participant in the morning after 12-hour overnight fast and all subjects were told to consume a bland diet before blood testing, and serum samples were separated immediately by centrifugation. Serum samples were stored at --80°C until analysis. Serum high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), total cholesterol (TCh), triglyceride (TG), small dense density lipoprotein (sdLDL), uric acid (UA), creatinine (Cr) were measured by enzymatic methods with commercially available kits on SEIMENS ADVIA 2400 (Siemens Healthcare Diagnostics ltd, Frimley, Camberley, UK). Lipoprotein(a) \[Lp(a)\], apolipoprotein A1 (ApoA1), and apolipoprotein B (Apo-B) levels were measured by immunoturbidimetric method, using reagent from SEIMENS ADVIA 2400 (Siemens Healthcare Diagnostics Inc, Akishima, Tokyo, Japan). Reference intervals were: ApoA1: 1.0--1.6 g/L, ApoB: 0.75--1.00 g/L, HDL-Ch: 1.00--1.55 mmol/L, LDLCh: 1.9--3.1 mmol/L, Lp(a): \<300 mg/L, TCh: 3.1--5.2 mmol/L, TG: 0.6--1.7 mmol/L, sdLDL: 0.25--1.17 mmol/L, UA: 155--357 µmol/L, Urea: 2.6--7.5 mmol/L, Cr: 41--73 µmol/L. In addition to Biochemical Measurement, the following risk factors were also recorded for each individual: Hyperuricemia, Hypertension, Hyperhomocysteinemia, Hyperlipidemia, Type 2 diabetes.

DNA extraction and *APOE* genotyping
------------------------------------

Genomic DNA was extracted from peripheral blood mononuclear cells by using a QIAamp DNA Blood Mini Kit \[Kaijie Enterprise Management (Shanghai) Co., Ltd., Xuhui, Shanghai, China\] following the manufacturer's instructions, and DNA concentration was quantified by using a NanoDrop 2000TM spectrophotometer (ThermoFisher Scientific, Waltham, MA, USA). PCR was performed according to the following protocol: 50°C for two minutes, pre-denaturation at 95°C for 15 minutes, followed by 45 cycles at 94°C for 30 seconds and 65°C for 45 seconds. The amplified products were detected by using an *APOE* Gene typing Detection kit (gene-chip assay) (Sinochips Bioscience Co., Ltd., Zhuhai, Guangdong, China) (@ Association of *APOE* Gene Polymorphisms with Cerebral Infarction in the Chinese Population).

Genetic analysis
----------------

The detection of three isoforms of the apoE protein (*E2*, *E3*, and *E4*) resulting from the polymorphisms of the gene was performed as described in the literature \[[@b17-pi-2019-0090]\].

Statistical analysis
--------------------

Statistical Package for the Social Sciences (SPSS) version 19.0 (IBM Corp., Armonk, NY, USA) was used for data analysis. The data were reported as mean±standard deviation (SD), quarter median and frequencies. The chi-square test and ANOVA were used to analyze the association between specific APOE genotypes and clinical characteristics. Multivariate logistic regression analysis was carried out to estimate the odds ratio (OR), with 95% confidence intervals (CI), in order to assess basic information, clinical indicators and APOE genotypes and alleles risk factors for progress of the disease. The results were considered to be significant differences when the p value was less than 0.05.

RESULTS
=======

Clinical characteristics of the patient and control groups
----------------------------------------------------------

As showed in [Table 1](#t1-pi-2019-0090){ref-type="table"}, comparison between disease group (White matter lesions, brain atrophy, Combined with white matter lesions and brain atrophy) and the controls indicated statistically significant differences in the clinical parameters, which included Gender (p\<0.0001), Age (p\<0.0001), ApoB (p\<0.0001), HDL-Ch (p=0.005), Lp(a) (p=0.001), TCh (p\< 0.0001), TG (p\<0.0001), sdLDL (p\<0.0001), UA (p\<0.0001), Urea (p=0.002), Cr (p\<0.0001), except for LDL-Ch and ApoA1.

The distribution and frequencies of the APOE genotypes and alleles in the patient and control groups
----------------------------------------------------------------------------------------------------

[Table 2](#t2-pi-2019-0090){ref-type="table"} showed that carriers of genotype *E3*/*E3* was the most common type in three groups (65.52%, 69.53%, 57.14% of White matter lesions, brain atrophy, and Combined with brain atrophy and white matter lesions groups, respectively), followed by *E3*/*E4* genotype (22.41%, 17.97% of White matter lesions and brain atrophy groups, respectively), but the genotype frequency of *E2*/*E3* was higher than *E3*/4 in Combined with white matter lesions and brain atrophy group (p=0.016). Allele *E3* was the most common allele, followed by allele *E4* and allele *E2* in White matter lesions, brain atrophy, and Combined with white matter lesions and brain atrophy groups, respectively (p=0.011). The type 2 diabetes of combined metabolic disease was significantly different among the three groups (p=0.015). However, others including Hyperuricemia, Hypertension, Hyperhomocysteinemia and Hyperlipidemia were not significantly different.

Comparison of metabolic parameters among the different ApoE alleles
-------------------------------------------------------------------

We further analyzed the effects of the *APOE* genotypes on the clinical and metabolic parameters in White matter lesions group. As shown in [Table 3](#t3-pi-2019-0090){ref-type="table"}, Age and the levels of ApoB and Urea were significantly different among the *APOE* genotype groups in White matter lesions group. Specifically, the subjects with an alleles *E4* was associated with the lowest level of Urea incidence (p=0.021), however, subjects with the alleles *E2* had significantly higher levels of ApoB and lower age compared with the *E3* and *E4* group (p=0.040, p=0.026, respectively). In addition, we compared the relationship between *ApoE* alleles and Combined metabolic disease, which was not statistically significant (p\>0.05).

Comparison of metabolic parameters among the different ApoE alleles
-------------------------------------------------------------------

We also analyzed the effects of the *APOE* genotypes on the clinical and metabolic parameters in brain atrophy group. As shown in [Table 4](#t4-pi-2019-0090){ref-type="table"}, there was no significantly different among clinical, metabolic parameters and *APOE* genotype groups in brain atrophy group (p\>0.05). The same conclusion appeared in the combined metabolic disease group (p\>0.05).

Comparison of metabolic parameters among the different *ApoE* alleles
---------------------------------------------------------------------

We finally analyzed the effects of the *APOE* alleles on the clinical and metabolic parameters in Combined with white matter lesions and brain atrophy group. As shown in [Table 5](#t5-pi-2019-0090){ref-type="table"}, the levels of ApoB, LDL-Ch, TCh, and sdLDL were significantly different among the *APOE* genotype groups in Combined with white matter lesions and brain atrophy group. Specifically, the subjects with an alleles *E2* was associated with the lower level of ApoB, LDL-Ch, TCh, and sdLDL compared with the *E3* and *E4* group (p\<0.0001, p\<0.0001, p=0.005, p= 0.002, respectively). In addition, we compared the relationship between ApoE alleles and combined metabolic disease, only Type 2 diabetes of combined metabolic disease was different among different *APOE* alleles (p=0.016).

Comparison of metabolic parameters among the different disease groups of the subjects with *E3*/*E3* genotype
-------------------------------------------------------------------------------------------------------------

As shown in [Table 6](#t6-pi-2019-0090){ref-type="table"}, clinical information including Gender and Age and the levels of sdLDL were significantly different among the different disease groups of the subjects with *E3*/*E3* genotype. Specifically, the subjects with White matter lesions has higher level of sdLDL but lower age and female frequency compared other disease groups (p=0.039, p\<0.0001, p=0.002, respectively). In addition, we compared the relationship between disease groups of the subjects with *E3*/*E3* genotype and combined metabolic disease, only type 2 diabetes of combined metabolic disease was significantly different in the three disease groups of the subjects with *E3*/*E3* genotype (p=0.004).

Comparison of metabolic parameters among the different disease groups of the subjects with *E3*/*E4* genotype
-------------------------------------------------------------------------------------------------------------

As shown in [Table 7](#t7-pi-2019-0090){ref-type="table"}, clinical information including age and the levels of ApoB and TG were significantly different among the different disease groups of the subjects with *E3*/*E4* genotype. Specifically, the subjects with White matter lesions has higher level of TG than other disease groups (p=0.013), but lower age than other disease groups (p=0.001, p=0.026, respectively). Interestingly, the subjects with brain atrophy has lower level of ApoB than other disease groups (p=0.026). In addition, we compared the relationship between disease groups of the subjects with *E3*/*E4* genotype and combined metabolic disease, there was no significantly different in the three disease groups of the subjects with *E3*/*E4* genotype (p\>0.05).

The multivariate logistic regression analysis of Basic Information, Clinical indicators and *APOE* among different disease groups
---------------------------------------------------------------------------------------------------------------------------------

[Table 8](#t8-pi-2019-0090){ref-type="table"} presents that Gender (p=0.012, OR=3.192, 95% CI: 1.289--7.904) and Age (p\<0.0001, OR=0.900, 95% CI: 0.860--0.942) of basic information and *E2* Allele(p=0.019, OR=0.197, 95% CI: 0.051--0.762) in White matter lesions group were also significantly associated with disease progression when Combined with white matter lesions and brain atrophy was set as the reference group. Similarly, the results showed that Hyperhomocysteinemia of Combined metabolic disease (p=0.023, OR=0.472, 95% CI: 0.247--0.900) and UA (p=0.004, OR=0.995, 95% CI: 0.992--0.999) in brain atrophy group were also significantly associated with disease progression when Combined with white matter lesions and brain atrophy was set as the reference group.

DISCUSSION
==========

Some articles have confirmed the clinical results of the presence of WML and brain atrophy on MRI \[[@b10-pi-2019-0090]\]. Previous studies have found that age and gender are risk factors for brain atrophy and white matter \[[@b18-pi-2019-0090],[@b19-pi-2019-0090]\]. However, few articles had reported the relationship between gender and alleles, genotypes in different diseases. Here we show that the prevalence of men in brain atrophy, co-occurrence of WML and brain atrophy disease group is higher than that of WML, the co-occurrence of WML and brain atrophy as a control group, the multivariate logistic analysis of clinical data showed that Gender was a risk factor and gender was a protective factor in the WML group in brain atrophy group. More importantly, *E4* allele carriers are older than *E2* and *E3* allele carriers in WML not in other disease groups. We also analyzed the relationship between clinical data, and different disease groups in *E3*/*E3* and *E3*/*E4* genotype group, respectively. The results showed that age, gender were significantly different in different disease groups of *E3*/*E3* carriers, while age was also significantly different in different disease groups of *E3*/*E4* carriers. Interestingly, the age of the cooccurrence group was higher than the other groups in both *E3*/*E3* and *E3*/*E4* groups. The above data indicates that age is closely related to the progression and type of disease and genotype, Allele.

According to a previous report cardiovascular disease is associated with high blood lipid levels, type 2 diabetes and other metabolic diseases, such as hyperhomocysteinemia, hyperuricemia, hypertension \[[@b20-pi-2019-0090]-[@b22-pi-2019-0090]\]. In the present study, the metabolic index of the disease group (including WML, brain atrophy, cooccurrence of WML and brain atrophy) was higher than that of the healthy group, although most of the indicators were within the normal reference range. It is worth mentioning that the uric acid concentration in the disease group is higher than the normal range. The multivariate logistic analysis of metabolic indicators showed that serum uric acid was a protective factor in brain atrophy group.

In the Chinese population, the predominant genotype is *E3*/*E3* in the Chinese population, whereas the most common allele is *E3*, followed by *E2*/*E3*, *E3*/*E4*, *E2*/*E4*, *E4*/*E4*, and *E2*/*E2* \[[@b2-pi-2019-0090]\].3-25 Our research also confirmed that *E3*/*E3* and *E3* were dominant. However, in this research, the *E3*/*E4* genotype follows the *E3*/*E3* genotype in WML group and brain atrophy group, respectively, but the *E2*/*E2* genotype follows the *E2*/*E3* genotype in the co-occurrence of WML and brain atrophy disease group. The same conclusion is given for *E2* and *E4* alleles. The difference in the above results may be that the proportion of *APOE* genotypes is related to the type of disease.

Since *APOE* gene polymorphism plays a key role in the regulation of plasma lipid levels \[[@b26-pi-2019-0090],[@b27-pi-2019-0090]\], APOE isoforms are thought to play an important role in the pathogenesis of vascular disease \[[@b28-pi-2019-0090],[@b29-pi-2019-0090]\]. The results show that, First, serum ApoB and urea levels of patients with WML are different among allele groups. In addition, ApoB level of E2 allele carriers was higher than others. Second, there is no difference in clinical data and metabolic indicators between different alleles of brain atrophy patients. Then, ApoB, LDL-Ch, TCh and sdLDL levels of the metabolic indicators of co-occurrence of WML and brain atrophy patients are significantly different among different alleles. It is worth mentioning that ApoB, LDL-Ch, TCh and sdLDL levels of *E2* carriers was lower than that of *E3* and *E4* carriers. The above conclusions can be speculated that the relationship between alleles and metabolic indicators is closely related to disease type and progression. Interestingly, genotype has a certain relationship with disease progression. Further analysis of genotypes and metabolic indicators revealed that sdLDL was significantly different in different disease groups of *E3*/*E3* carriers, while APOB and TG were significantly different in different disease groups of *E3*/*E4* carriers.

Metabolic disorder can lead to a greater potential of type 2 diabetes, lipid disorders, cardiovascular disease, hepatic steatosis, and other circulatory disorders \[[@b30-pi-2019-0090],[@b31-pi-2019-0090]\]. We found that the incidence of type 2 diabetes has significant differences among three disease groups. In addition, type 2 diabetes also has significant differences among different allele groups of co-occurrence group, not WML and brain atrophy groups. Further comparison of the incidence of metabolic complications among different disease groups of the certain genotype, and found that type 2 diabetes has significant differences among different diseases groups of *E3*/*E3* carriers, rather than *E3*/*E4* carriers.

At last, multivariate logistic regression analysis of the factors affecting the disease progression, the co-infected group as a control group, the data show that gender is a risk factor \[3.192 (1.289--7.904)\], age \[0.900 (0.860--0.942)\] and *E2* allele \[2020-02-10;0.197 (0.051-0.762)\] are protective factors for white matter disease. In the same way, hyperhomocysteinemia \[0.472 (0.247--0.900)\] and uric acid \[0.995 (0.992--0.999)\] are protective factors for brain atrophy.
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###### 

Comparison of clinical data between disease group and control group

  Clinical characteristics   WML (N=58)                Brain atrophy (N=128)     Co-occurrence of WML and brain atrophy (N=112)   Control group (N=95)   p value
  -------------------------- ------------------------- ------------------------- ------------------------------------------------ ---------------------- ----------
  Gender (male, %)           29 (50.00)                92 (71.88)                73 (65.18)                                       38 (40.00)             \<0.0001
  Age (years)                62.9±10.06                70.58±9.54                71.58±8.89                                       64.12±10.66            \<0.0001
  ApoA1 (g/L)                1.35±0.222                1.31±0.206                1.30±0.202                                       1.26±0.187             0.050
  ApoB (g/L)                 0.93±0.24                 0.85±0.25                 0.84±0.24                                        0.73±0.157             \<0.0001
  HDL-Ch (mmol/L)            1.05 (0.83--1.25)         1.00 (0.84--1.17)         1.05 (0.88--1.21)                                1.15 (0.98--1.32)      0.005
  LDL-Ch (mmol/L)            2.52 (1.83--2.95)         2.30 (1.71--2.92)         2.28 (1.6 0--2.84)                               2.14 (1.72--2.76)      0.240
  Lp(a) (mg/L)               199.40 (97.00--477.33)    137.45 (70.40--332.25)    134.10 (71.10--429.00)                           118 (55.2--183)        0.001
  TCh (mmol/L)               4.53 (3.79--5.18)         4.21 (3.57--4.90)         4.08 (3.43--4.87)                                3.83 (3.39--4.39)      \<0.0001
  TG (mmol/L)                1.41 (1.07--2.23)         1.25 (0.99 --1.78)        1.32 (0.90--1.68)                                0.97 (0.75--1.18)      \<0.0001
  sdLDL (mmol/L)             0.92 (0.58--1.22)         0.78 (0.54--1.06)         0.71 (0.48--1.01)                                0.57 (0.46--0.75)      \<0.0001
  UA (µmol/L)                372.50 (322.50--447.75)   362.50 (299.50--432.25)   386.00 (307.00--486.00)                          259 (210--296)         \<0.0001
  Urea (mmol/L)              4.77 (3.92--5.61)         5.31 (4.25--6.43)         5.22 (4.30--6.44)                                4.56 (3.85--5.65)      0.002
  Cr (µmol/L)                66.50 (55.50--77.00)      73.00 (63.00--84.50)      72.00 (58.00--89.00)                             55 (49--62)            \<0.0001

ε2 allele=ε2/ε2+ε2/ε3 genotypes; ε3 allele=ε3/ε3+ε2/ε4; genotype; ε4 allele=ε3/ε4+ε4/ε4 genotypes. All values were adjusted for ethnicity, age and gender except the PWV was adjusted for age, SBP and ethnicity. Biological reference interval: ApoA1: 1--1.6 g/L; ApoB: 0.75--1.0 g/L; HDL-Ch: 1.0--1.55 mmol/L; LDL-Ch: 1.9--3.1 mmol/L; Lp(a): \<300 mg/L; TCh: 3.1--5.2 mmol/L; TG: 0.56--1.70 mmol/L; sdLDL: 0.25--1.17 mmol/L; UA: 155--357 μmol/L; Urea: 2.6--7.5 mmol/L; Cr: 41--73 μmol/L. ApoA1: Apolipoprotein A, ApoB: apolipoprotein B, HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, Lp(a): lipoprotein (a), TCh: total cholesterol, TG: triglyceride, sdLDL: small dense density lipoprotein, UA: uric acid, Cr: creatinine, WML: White matter lesions

###### 

Association of *apoE* Allele and genotype between disease group and control group

  Clinical characteristics         WML          Brain atrophy   Co-occurrence of WML and brain atrophy   p value
  -------------------------------- ------------ --------------- ---------------------------------------- ---------
  Genotype (%)                                                                                           0.016
   *E2/2*                          2 (3.45)     0 (0.00)        2 (1.79)                                 
   *E2/3*                          3 (5.17)     13 (10.16)      25 (22.32)                               
   *E2/4*                          0 (0.00)     3 (2.34)        2 (1.79)                                 
   *E3/3*                          38 (65.52)   89 (69.53)      64 (57.14)                               
   *E3/4*                          13 (22.41)   23 (17.97)      17 (15.18)                               
   *E4/4*                          2 (3.45)     0 (0.00)        2 (1.79)                                 
  Allele (%)                                                                                             0.011
   *E2*                            5 (8.62)     13 (10.16)      27 (24.11)                               
   *E3*                            38 (65.52)   92 (71.88)      66 (58.93)                               
   *E4*                            15 (25.86)   23 (17.97)      19 (16.96)                               
  Combined metabolic disease (%)                                                                         
   Hyperuricemia                   16 (27.59)   30 (23.44)      37 (33.04)                               0.254
   Hypertension                    42 (72.41)   79 (61.72)      75 (66.96)                               0.343
   Hyperhomocysteinemia            12 (20.69)   46 (35.94)      28 (25.00)                               0.054
   Hyperlipidemia                  20 (34.48)   33 (25.78)      32 (28.57)                               0.477
   Type 2 diabetes                 11 (18.97)   43 (33.59)      21 (18.75)                               0.015

ε2 allele=ε2/ε2+ε2/ε3 genotypes; ε3 allele=ε3/ε3 genotype; ε4 allele=ε3/ε4+ε4/ε4 genotypes. WML: White matter lesions

###### 

Comparison of baseline characteristics of participants with *E2*, *E3*, and *E4* alleles in WML

  Genotype                         E2 (N=5)                  E3 (N=38)                E4 (N=15)           p value
  -------------------------------- ------------------------- ------------------------ ------------------- ---------
  Gender (male%)                   4 (4/5)                   15 (15/38)               10 (10/15)          0.076
  Age (years)                      60.40±5.550               61.79±10.624             66.53±9.234         0.026
  ApoA1 (g/L)                      1.50±0.255                1.32±.234                1.36±0.162          0.218
  ApoB (g/L)                       1.05 (1.04--1.24)         0.85 (0.77--1.03)        0.89 (0.69--1.02)   0.040
  HDL-Ch (mmol/L)                  1.23±0.430                1.07±0.342               1.05±0.202          0.516
  LDL-Ch (mmol/L)                  3.02±1.085                2.49±0.821               2.38±0.816          0.342
  Lp(a) (mg/L)                     208.00 (92.30--1000.10)   190.30 (85.25--343.13)   222.50 (100--727)   0.717
  TCh (mmol/L)                     5.15±1.020                4.56±1.076               4.49±0.944          0.453
  TG (mmol/L)                      1.28 (1.04--2.46)         1.36 (0.97--2.23)        1.52 (1.08--2.41)   0.895
  sdLDL (mmol/L)                   1.08±0.254                0.94±0.381               0.87±0.423          0.569
  UA (µmol/L)                      331 (239--377.5)          398 (335.5--456.5)       381(297--444)       0.102
  Urea (mmol/L)                    5.12 (4.72--6.62)         5.13 (4.20--5.99)        3.83 (3.21--4.78)   0.021
  Cr (µmol/L)                      63 (47--84.5)             66.5 (56.75--73.25)      69 (51--88)         0.937
  Combined metabolic disease (%)                                                                          
   Hyperuricemia                   1 (20.00)                 10 (26.35)               5 (33.33)           0.809
   Hypertension                    5 (100)                   24 (63.15)               13 (86.67)          0.080
   Hyperhomocysteinemia            3 (60.00)                 6 (15.79)                3 (20.00)           0.072
   Hyperlipidemia                  2 (13.33)                 12 (31. 58)              6 (40.00)           0.814
   Type 2 diabetes                 0 (0.00)                  8 (21.05)                3 (20.00)           0.525

ε2 allele=ε2/ε2+ε2/ε3 genotypes; ε3 allele=ε3/ε3+ε2/ε4, genotype; ε4 allele=ε3/ε4+ε4/ε4 genotypes. WML: White matter lesions

###### 

Comparison of baseline characteristics of participants with *E2*, *E3* and *E4* alleles in brain atrophy

  Genotype                         E2 (N=13)           E3 (N=92)              E4 (N=23)              p value
  -------------------------------- ------------------- ---------------------- ---------------------- ---------
  Gender (male%)                   11 (11/13)          67 (67/92)             14 (14/23)             0.292
  Age (years)                      69 (63.5--76)       68 (6325--78.75)       74 (68--83)            0.054
  ApoA1 (g/L)                      1.33±0.193          1.32±0.210             1.26±0.193             0.423
  ApoB (g/L)                       0.88±0.327          0.86±0.236             0.80±0.241             0.599
  HDL-Ch (mmol/L)                  1 (0.88--1.26)      1.01 (0.84--1.13)      0.98 (0.85--1.24)      0.874
  LDL-Ch (mmol/L)                  2.8 (1.48--3.27)    2.3 (1.72--2.96)       2.25 (1.76--2.75)      0.839
  Lp(a) (mg/L)                     254 (54.95--461)    131.5 (70.4--317.75)   137 (73.7--345)        0.831
  TCh (mmol/L)                     4.06 (3.37--5.16)   4.28 (3.67--4.97)      3.85 (3.24--4.37)      0.376
  TG (mmol/L)                      1.24 (1.04--2.51)   1.27 (0.98--1.83)      1.17 (0.89--1.50)      0.518
  sdLDL (mmol/L)                   0.89±0.374          0.83±0.389             0.78±0.440             0.763
  UA (µmol/L)                      381.62±89.511       369.64±116.971         346.74±94.852          0.595
  Urea (mmol/L)                    4.82 (3.4--5.88)    5.34 (4.35--6.45)      5.77 (4.04--6.44)      0.277
  Cr (µmol/L)                      76 (66--80.5)       72.5 (63.00--85.00)    73.00 (62.00--86.00)   0.974
  Combined metabolic disease (%)                                                                     
   Hyperuricemia                   4 (30.77)           23 (25.00)             3 (13.04)              0.387
   Hypertension                    9 (69.23)           59 (64.13)             11 (47.83)             0.299
   Hyperhomocysteinemia            4 (30.77)           32 (34.78)             10 (43.48)             0.680
   Hyperlipidemia                  6 (46.15)           24 (26.09)             3 (13.04)              0.092
   Type 2 diabetes                 3 (23.08)           35 (38.04)             5 (21.74)              0.233

ε2 allele=ε2/ε2+ε2/ε3 genotypes; ε3 allele=ε3/ε3+ε2/ε4, genotype; ε4 allele=ε3/ε4+ε4/ε4 genotypes

###### 

Comparison of baseline characteristics of participants with *E2*, *E3*, and *E4* alleles in co-occurrence of WML and brain atrophy

  Genotype                         E2 (N=27)              E3 (N=66)                 E4 (N=19)              p value
  -------------------------------- ---------------------- ------------------------- ---------------------- ----------
  Gender (male%)                   18 (18/27)             41 (41/66)                14 (14/19)             0.636
  Age (years)                      74 (67--80.25)         71 (66--78.25)            68 (64--77)            0.644
  ApoA1 (g/L)                      1.27±0.184             1.30±0.218                1.32±0.169             0.716
  ApoB (g/L)                       0.70±0.242             0.86±0.216                0.98±0.219             \<0.0001
  HDL-Ch (mmol/L)                  1.02 (0.82--1.19)      1.07 (0.86--1.23)         1.06 (0.92--1.14)      0.571
  LDL-Ch (mmol/L)                  1.75±0.801             2.31±0.788                2.74±0.804             \<0.0001
  Lp(a) (mg/L)                     131.45 (67.82--491)    140.05 (79.50--431)       108 (54.60--353.10)    0.653
  TCh (mmol/L)                     3.73±1.007             4.21±1.030                4.77±1.128             0.005
  TG (mmol/L)                      1.24 (0.87--1.68)      1.32 (0.90--1.66)         1.46 (1.10--2.35)      0.277
  sdLDL (mmol/L)                   0.63±.351              0.75±0.319                1.00±0.392             0.002
  UA (µmol/L)                      406 (294.25--493.75)   360.50 (297.25--446.25)   427 (326--468)         0.384
  Urea (mmol/L)                    4.79 (4.38--6.26)      5.60 (4.38--6.63)         4.60 (3.90--6.95)      0.348
  Cr (µmol/L)                      76 (61--85.50)         68.50 (57.00--95.00)      77.00 (57.00--93.00)   0.949
  Combined metabolic disease (%)                                                                           
   Hyperuricemia                   11 (40.74)             20 (30.30)                6 (31.58)              0.617
   Hypertension                    19 (70.37)             43 (65.15)                13 (68.42)             0.879
   Hyperhomocysteinemia            6 (22.22)              19 (28.79)                3 (15.79)              0.478
   Hyperlipidemia                  8 (29.63)              18 (27.27)                6 (46.15)              0.926
   Type 2 diabetes                 4 (14.81)              9 (13.64)                 8 (42.11)              0.016

ε2 allele=ε2/ε2+ε2/ε3 genotypes; ε3 allele=ε3/ε3+ε2/ε4, genotype; ε4 allele=ε3/ε4+ε4/ε4 genotypes. WML: White matter lesions

###### 

Comparison of clinical data and complications among three disease groups of APOE *E3/E3*

  Genotype                         WML (N=38)                Brain atrophy (N=89)      Co-occurrence of WML and brain atrophy (N=64)   p value
  -------------------------------- ------------------------- ------------------------- ----------------------------------------------- ----------
  Gender (male, %)                 15 (39.47)                65 (73.03)                40 (62.50)                                      0.002
  Age (years)                      61.79±10.624              69.61±9.822               71.78±8.682                                     \<0.0001
  ApoA1 (g/L)                      1.32±0.234                1.32±0.213                1.30±0.216                                      0.738
  ApoB (g/L)                       0.85 (0.77--1.03)         0.86 (0.64--1.03)         0.87 (0.71--1.01)                               0.599
  HDL-Ch (mmol/L)                  1.02 (0.79--1.25)         1.01 (0.84--1.13)         1.05 (0.86--1.22)                               0.852
  LDL-Ch (mmol/L)                  2.52 (1.83--2.85)         2.30 (1.71--2.96)         2.29 (1.70--2.88)                               0.678
  Lp(a) (mg/L)                     190.30 (85.25--343.13)    132.00 (70.15--329.50)    133.55 (78.50--423.43)                          0.420
  TCh (mmol/L)                     4.56±1.076                4.30±1.020                4.19±0.986                                      0.199
  TG (mmol/L)                      1.36 (0.97--2.23)         1.27 (0.98--1.82)         1.32 (0.91--1.67)                               0.287
  sdLDL (mmol/L)                   0.94±0.381                0.83±0.395                0.75±0.313                                      0.039
  UA (µmol/L)                      398.00 (335.50--456.50)   364.00 (302.50--441.00)   363.50 (300.25--468.75)                         0.312
  Urea (mmol/L)                    5.13 (4.20--5.99)         5.36 (4.40--6.45)         5.55 (4.35--6.68)                               0.483
  Cr (µmol/L)                      66.50 (56.75--73.25)      72.00 (63.00--84.00)      68.50 (57.00--95.00)                            0.150
  Combined metabolic disease (%)                                                                                                       
   Hyperuricemia                   10 (26.32)                22 (24.72)                20 (31.25)                                      0.663
   Hypertension                    24 (63.16)                57 (64.04)                41 (64.06)                                      0.995
   Hyperhomocysteinemia            6 (15.79)                 31 (34.83)                18 (28.13)                                      0.094
   Hyperlipidemia                  12 (31.58)                24 (26.97)                17 (26.56)                                      0.839
   Type 2 diabetes                 8 (21.05)                 33 (37.08)                9 (14.06)                                       0.004

WML: White matter lesions

###### 

Comparison of clinical data and complications among three disease groups of APOE *E3/E4*

  Genotype                     WML (N=13)          brain atrophy (N=23)   Co-occurrence of WML and brain atrophy (N=17)   p value
  ---------------------------- ------------------- ---------------------- ----------------------------------------------- ---------
  Gender (male, %)             10 (76.92)          14 (60.87)             13 (76.47)                                      0.462
  Age (years)                  63.92±6.383         74.83±8.516            71.00±8.208                                     0.001
  ApoA1 (g/L)                  1.39±.150           1.26±.193              1.33±0.173                                      0.095
  ApoB (g/L)                   0.93±.220           0.80±.241              1.01±0.215                                      0.026
  HDL-Ch(mmol/L)               1.12 (0.86--1.23)   098 (0.85--1.24)       1.07 (0.93--1.29)                               0.501
  LDL-Ch(mmol/L)               2.51±0.783          2.25±0.765             2.84±0.796                                      0.073
  Lp(a) (mg/L)                 191 (89.9--679.1)   137 (73.7--345)        108 (54.8--301.05)                              0.453
  TCh (mmol/L)                 4.64 (3.86--5.13)   3.85 (3.24--4.37)      4.76 (4.25--5.48)                               0.049
  TG (mmol/L)                  1.53 (1.31--2.50)   1.17 (0.89--1.50)      1.46 (1.13--2.52)                               0.013
  sdLDL (mmol/L)               0.96±0.387          0.78±0.440             1.03±0.407                                      0.174
  UA (µmol/L)                  381.38±92.151       346.74±94.852          416.65±103.780                                  0.089
  Urea (mmol/L)                4.24±1.208          5.43±1.435             5.16±1.690                                      0.071
  Cr (µmol/L)                  66.31±24.243        74.35±15.865           73.12±18.415                                    0.459
  Combined metabolic disease                                                                                              
   Hyperuricemia               4 (30.77)           3 (13.04)              6 (35.29)                                       0.226
   Hypertension                11 (84.62)          11 (47.83)             12 (70.59)                                      0.069
   Hyperhomocysteinemia        3 (23.08)           10 (43.48)             3 (17.65)                                       0.173
   Hyperlipidemia              5 (38.46)           3 (13.04)              6 (35.29)                                       0.151
   Type 2 diabetes             2 (15.38)           5 (21.74)              7 (41.18)                                       0.226

WML: White matter lesions

###### 

Multivariate logistic regression analysis among different disease groups

                               WML                   Brain atrophy                                      
  ---------------------------- --------------------- --------------- ---------- ------- --------------- -------
  Basic information                                                                                     
   Gender                      3.192                 1.289--7.904    0.012      0.707   0.353--1.412    0.326
   Age                         0.900                 0.860--0.942    \<0.0001   0.995   0.963--1.029    0.771
  Combined metabolic disease                                                                            
   Hyperhomocysteinemia        0.823                 0.327--2.073    0.680      0.472   0.247--0.900    0.023
   Hyperuricemia               1.019                 0.398--2.609    0.968      0.843   0.400--1.777    0.653
   Hypertension                0.705                 0.302--1.646    0.419      1.291   0.705--2.364    0.408
   Hyperlipidemia              1.188                 0.468--3.015    0.717      1.280   0.612--2.675    0.512
   Diabetes                    1.223                 0.480--3.114    0.673      0.521   0.266--1.024    0.059
  Clinical indicators                                                                                   
   UA                          0.999                 0.995--1.003    0.587      0.995   0.992--0.999    0.004
   ApoA1                       0.562                 0.021--15.256   0.732      1.165   0.097--14.003   0.904
   ApoB                        0.405                 0.003--56.254   0.719      0.186   0.004--8.247    0.385
   HDL-Ch                      4.131                 0.232--73.637   0.335      1.861   0.220--15.764   0.569
   LDL-Ch                      1.755                 0.351--8.774    0.494      2.308   0.591--9.014    0.229
   Lp(a)                       1.001                 0.999--1.002    0.341      1.000   0.999--1.001    0.427
   TCh                         0.652                 0.172--2.468    0.529      0.658   0.211--2.049    0.470
   TG                          1.437                 0.649--3.181    0.371      1.571   0.811--3.043    0.180
   sdLDL                       3.007                 0.337--26.842   0.324      1.683   0.324--8.739    0.536
   Urea                        0.921                 0.733--1.158    0.480      0.963   0.810--1.145    0.670
   Cr                          0.997                 0.975--1.020    0.820      1.001   0.993--1.009    0.813
  Allele                                                                                                
   E=2                         0.197                 0.051--0.762    0.019      0.514   0.191--1.381    0.187
   E=3                         0.508                 0.199--1.296    0.157      1.305   0.617--2.762    0.486
   E=4                         The reference group                                                      
  Genotype                                                                                              
   APOE=E2/2+E2/4+E4/4         0.527                 0.082--3.399    0.500      0.689   0.120--3.964    0.676
   APOE=E2/3                   0.210                 0.043--1.026    0.054      0.468   0.166--1.316    0.150
   APOE=E3/3                   0.985                 0.377--2.572    0.976      1.154   0.531--2.510    0.717
   APOE=E3/4                   The reference group                                                      

co-occurrence of WML and brain atrophy was set as the reference group. WML: White matter lesions
